JCEM case reports links tirzepatide to recurrent hordeola in two patients
One patient's lesions eased after stopping the drug and worsened on rechallenge, which the authors call strong evidence of causality.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 16 20:00 ETSource: JCEM case reports
The wire
- 01Two women, aged 44 and 73, each developed six simultaneous internal hordeola, several progressing to chalazia, 4 and 10 weeks after tirzepatide dose escalation or initiation at 5 mg.
- 02The authors describe this as the first reported eyelid gland association with GLP-1/GIP agonists and advise conservative ophthalmic management before changing therapy.
- 03This is a two-patient case series; absence of classic infectious signs suggests a sterile meibomian gland process, but incidence and mechanism remain unknown.
From the source
Read at pubmed.ncbi.nlm.nih.govSimultaneous and recurrent hordeola and chalazia associated with tirzepatide therapy: a case series
JCEM case reports · 2026 Oct · Kolker A et al.
Source URL https://pubmed.ncbi.nlm.nih.gov/42756500/